You are here: Industry Insights > SPMS

News List

NICE rejects Novartis' Mayzent for secondary progressive MS pharmatimes
June 29, 2020
NICE has turned down NHS funding in preliminary guidelines for use of Novatis' Mayzent (siponimod) as a treatment for secondary progressive multiple sclerosis (SPMS) with evidence of active disease.
Novartis highlights benefits of Mayzent in MS pharmatimes
April 22, 2020
New data showing the benefits of Novartis' Mayzent (siponimod) in patients with secondary progressive multiple sclerosis (SPMS) have been published in the April supplemental issue of American Academy of Neurology.
FDA approves Novartis’ oral multiple sclerosis drug Mayzent pharmaceutical-technology
April 11, 2019
Novartis has obtained approval from the US Food and Drug Administration (FDA) for its relapsing multiple sclerosis (RMS) drug Mayzent (siponimod)...
The biggest ever trial for secondary progressive multiple sclerosis (SPMS) has kicked off in the UK at around 30 sites in England, Scotland, Wales, Northern Ireland and Eire. pharmatimes
September 18, 2018
The biggest ever trial for secondary progressive multiple sclerosis (SPMS) has kicked off in the UK at around 30 sites in England, Scotland, Wales, Northern Ireland and Eire.
US, EU filings imminent for Novartis’ MS therapy siponimod pharmatimes
July 20, 2018
Novartis’ experimental multiple sclerosis therapy siponimod is on the brink of being filed in the US.